<DOC>
	<DOCNO>NCT01047475</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , placebo-controlled study evaluate preliminary efficacy safety MB-6 ( 320 mg/capsule , 6 capsule tid ) versus placebo addition standard chemotherapy treatment patient metastatic colorectal cancer .</brief_summary>
	<brief_title>A Phase II Trial MB-6 Plus FOLFOX4 Metastatic Colorectal Cancer ( FDA IND 103675 )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Patient histologically confirm colorectal cancer and/or clinical evidence metastasis ; 2 . At least one measurable lesion either computer tomography ( CT ) scan magnetic resonance imaging ( MRI ) ; 3 . Aged 20 year old ; 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ; 5 . Adequate bone marrow reserve ( hemoglobin &gt; 9 g/dl , absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) ; 6 . Adequate renal hepatic function : total bilirubin &lt; 1.25 x upper normal limit , creatinine &lt; 1.25 x upper normal limit , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x upper normal limit ; 7 . Patients willing participate trial give write informed consent . 1 . Pregnant lactating patient ; 2 . Patients ( male female ) reproductive potential use adequate contraceptive measure ; 3 . Patients evidence central nervous system metastasis ; 4 . Subject active infection require systemic treatment antibiotic , antifungal , antiviral agent 5 . Current history chronic diarrhea ; 6 . Other serious illness medical condition ( e.g . : history angina , myocardial infarction ) ; 7 . History second primary malignancy except adequately treat basal cell carcinoma skin carcinoma situ cervix ; 8 . Concurrent treatment anticancer therapy ; 9 . Patients congestive heart failure ( New York Heart Association Functional Classification III IV ) , epilepsy , significant medical condition judge investigator ; 10 . Patients treat another investigational drug within 4 week entry study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MB-6</keyword>
	<keyword>FOLFOX4</keyword>
	<keyword>Metastatic Colorectal Cancer</keyword>
</DOC>